Reliance Global Posts $1.99M Q2 Loss, Stock Near 52-Week Low
EZRA is trading near its 52-week low of $1.75 (2.9% above the low) on elevated volume (3.7× avg).
Summary
Reliance Global Group reported a Q2 net loss of $1.99 million, adding to ongoing losses as the company trades near its 52-week low of $1.75. The loss follows a transformative investment in Innervate and the launch of its LifeSci Global biotech division in May, but the financials show no near-term profitability. With a market cap of just $1.1 million and an active ATM program, the company remains deeply speculative. The reverse split in May temporarily addressed Nasdaq compliance, but the stock has since drifted back to pre-split levels. No revenue or cash burn figures were disclosed, leaving the runway unclear.
At the time of this announcement, EZRA was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $1.75 to $78.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.